TY - JOUR
T1 - Mitochondrial diseases of the brain.
AU - Chaturvedi,Rajnish K,
AU - Flint Beal,M,
Y1 - 2013/04/06/
PY - 2011/08/22/received
PY - 2013/03/21/revised
PY - 2013/03/22/accepted
PY - 2013/4/10/entrez
PY - 2013/4/10/pubmed
PY - 2013/11/2/medline
KW - 1-methyl-4-phenyl-1,2,3,6-tetrahydrodropyridine
KW - 1-methyl-4-phenylpyridinium
KW - 6-OHDA
KW - 6-hydroxydopamine
KW - AD
KW - ALS
KW - AMP-activated protein kinase
KW - AMPK
KW - Alzheimer’s disease
KW - Amyotrophic Lateral Sclerosis
KW - Amyotrophic lateral sclerosis
KW - BAT
KW - CK
KW - Charcot-Marie-Tooth disease and Friedreich’s ataxia
KW - Co-Q10
KW - CoQ10
KW - Creatine
KW - Drp1
KW - Free radicals
KW - HD
KW - Huntington’s Disease
KW - Huntington’s disease
KW - KGDH
KW - MFN
KW - MMP
KW - MPP+
KW - MPTP
KW - Mitochondrial dysfunction
KW - Neurodegenerative diseases
KW - PCr
KW - PD
KW - PGC-1α
KW - PPARs
KW - Parkinson’s disease
KW - ROS
KW - Sirtuins
KW - TAR DNA
KW - TCA
KW - TORC
KW - Tfam
KW - Transduceres of Creb-related binding protein
KW - UCP-1
KW - alpha-ketoglutarate dehydrogenase
KW - binding protein TDP-43
KW - brown adipose tissue
KW - coenzymeQ10
KW - creatine kinase
KW - dynamin-related protein 1
KW - mitochondrial DNA
KW - mitochondrial membrane potential
KW - mitochondrial transcription factor A
KW - mitofusin
KW - mtDNA
KW - peroxisome proliferator-activated receptors
KW - phosphocreatine
KW - proliferator-activated receptor-gamma coactivator-1alpha
KW - reactive oxygen species
KW - tricarboxylic acid cycle
KW - uncoupling proteins
SP - 1
EP - 29
JF - Free radical biology & medicine
JO - Free Radic Biol Med
VL - 63
N2 - Neurodegenerative disorders are debilitating diseases of the brain, characterized by behavioral, motor and cognitive impairments. Ample evidence underpins mitochondrial dysfunction as a central causal factor in the pathogenesis of neurodegenerative disorders including Parkinson's disease, Huntington's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, Friedreich's ataxia and Charcot-Marie-Tooth disease. In this review, we discuss the role of mitochondrial dysfunction such as bioenergetics defects, mitochondrial DNA mutations, gene mutations, altered mitochondrial dynamics (mitochondrial fusion/fission, morphology, size, transport/trafficking, and movement), impaired transcription and the association of mutated proteins with mitochondria in these diseases. We highlight the therapeutic role of mitochondrial bioenergetic agents in toxin and in cellular and genetic animal models of neurodegenerative disorders. We also discuss clinical trials of bioenergetics agents in neurodegenerative disorders. Lastly, we shed light on PGC-1α, TORC-1, AMP kinase, Nrf2-ARE, and Sirtuins as novel therapeutic targets for neurodegenerative disorders.
SN - 1873-4596
UR - https://www.unboundmedicine.com/medline/citation/23567191/Mitochondrial_diseases_of_the_brain_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0891-5849(13)00123-8
DB - PRIME
DP - Unbound Medicine
ER -